Roivant Sciences (ROIV) CFO uses 1,000 shares to settle RSU taxes

Rhea-AI Filing Summary

Roivant Sciences Ltd. reported that CFO Richard Pulik had 1,000 common shares withheld at a price of $27.15 per share to cover tax obligations from the vesting of previously granted RSUs. After this tax-withholding disposition, he directly holds 238,413 common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pulik Richard

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON X0 SW1H 0DB

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/20/2026		F		1,000(1)	D	$27.15	238,413	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

Remarks:

	By: /s/ Jo Chen, as Attorney-in-Fact for Richard Pulik	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Roivant Sciences (ROIV) report for its CFO?

Roivant Sciences reported that CFO Richard Pulik had 1,000 common shares withheld to satisfy tax obligations on vesting RSUs. This Form 4 reflects a tax-withholding disposition, not an open-market purchase or sale of shares.

How many Roivant Sciences (ROIV) shares were involved in the CFO’s Form 4?

The Form 4 shows 1,000 common shares of Roivant Sciences were withheld. These shares were used to cover applicable tax withholding obligations related to the vesting and settlement of previously granted restricted stock units (RSUs).

What price was used for the Roivant Sciences (ROIV) CFO tax-withholding shares?

The reported tax-withholding disposition used a price of $27.15 per Roivant Sciences common share. This price is applied solely for reporting the value of the 1,000 shares withheld to satisfy the CFO’s RSU-related tax obligations.

How many Roivant Sciences (ROIV) shares does the CFO hold after this transaction?

Following the tax-withholding disposition, CFO Richard Pulik directly holds 238,413 Roivant Sciences common shares. This reflects his remaining ownership after 1,000 shares were net settled to pay taxes on vesting RSUs reported in the Form 4.

Was the Roivant Sciences (ROIV) CFO’s Form 4 an open-market sale of shares?

No. The Form 4 describes a tax-withholding disposition via net settlement of RSUs. The issuer withheld 1,000 shares to cover tax obligations, rather than the CFO executing an open-market sale of Roivant Sciences stock.